CoVSense: Ultrasensitive Nucleocapsid Antigen Immunosensor for Rapid Clinical Detection of Wildtype and Variant SARS‐CoV‐2

Abstract The widespread accessibility of commercial/clinically‐viable electrochemical diagnostic systems for rapid quantification of viral proteins demands translational/preclinical investigations. Here, Covid‐Sense (CoVSense) antigen testing platform; an all‐in‐one electrochemical nano‐immunosensor for sample‐to‐result, self‐validated, and accurate quantification of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) nucleocapsid (N)‐proteins in clinical examinations is developed. The platform's sensing strips benefit from a highly‐sensitive, nanostructured surface, created through the incorporation of carboxyl‐functionalized graphene nanosheets, and poly(3,4‐ethylenedioxythiophene) polystyrene sulfonate (PEDOT:PSS) conductive polymers, enhancing the overall conductivity of the system. The nanoengineered surface chemistry allows for compatible direct assembly of bioreceptor molecules. CoVSense offers an inexpensive (